Ozuriftamab Vedotin

N/A

Report date: 2024/07/24 09:27:56

Base Information

Drug NameOzuriftamab Vedotin
Drug Alias NameROR-2 conditionally active biologic antibody based drug conjugate(BioAtla)RoR-2 conditionally active biologic antibody-drug conjugate(BioAtla)CAB-ROR2CAB-ROR2-ADCCAB-ADC +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTyrosine-protein kinase transmembrane receptor ROR2 inhibitorsWnt signalling pathway modulatorsTubulin inhibitors
TargetsTyrosine-protein kinase transmembrane receptor ROR2Tubulin
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBioAtla Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBristol-Myers Squibb CompanyKaibosi (Shanghai) Biomedical Co LtdBioAtla Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A